Found 98 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
A Single-blind Phase 2 Multi-center Randomized Study to Assess Safety Tolerability Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
The OVAL Study: A Randomized Controlled Double-Arm Double-Blind Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
This double-blind, randomized controlled trial will examine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer.
STRIDE Study : The Effects of semaglutide on functional capacity in pith type 2 diabetes and peripheral arterial disease
This is a 52 week, randomized, double-blind, placebo-controlled trial comparing semaglutide 1 mg versus placebo both added to standard of care and administered once weekly in subjects with Type 2 Diabetes Mellitus with Intermittent Claudication.
A randomized double-blind placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)
The present confirmatory phase 3 trial will be conducted to further investigate the efficacy and safety of molgramostim in subjects with aPAP. Investigating how molgramostim improves lung pathology, pathophysiology, and health status in subjects with aPAP in a dose- frequency dependent fashion.
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Randomized Double-Blind Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
The objectives of the study are to assess the safety and efficacy of elezanumab in subjects with acute traumatic cervical SCI. The primary endpoint is the Upper Extremity Motor Score (UEMS), a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI, 2019 criteria) during the treatment …
Phase 3 Multicenter Randomized Double-blind Trial of Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder
Patients with post-traumatic stress disorder (PTSD) will be invited to participate in this research study. Participants will be assigned to take one of the following: brexpiprazole, sertraline (also known as “Zoloft”; a marketed antidepressant that has been approved by the United States FDA for the treatment of PTSD), placebo (a …
Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis (RheSolve)
Prospective, randomized, parallel group, double-blind, concurrently controlled, multi-center clinical trial following patients to 2 years to assess the safety and effectiveness the treatment of the symptoms of chronic bronchitis in adult COPD patients with moderate to severe chronic bronchitis.
Please choose between Voice or SMS based delivery of verification code
or